Effective prevention of drug-induced risks depends on an accurate understanding of their triggering or predisposing factors, and the quality of information on these available to prescribing practitioners and users. All preclinical and clinical data available on the proprietary medicinal product concerned should facilitate identification of a risk, and these data should be compared with existing data on drugs sharing the same mode of action or therapeutic strategy. This information should be based on a communication plan adapted to the context of the disease under treatment, the therapeutic alternatives available and the benefits expected.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2515/therapie:2003035 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!